全文获取类型
收费全文 | 340篇 |
免费 | 14篇 |
专业分类
妇产科学 | 8篇 |
基础医学 | 20篇 |
临床医学 | 16篇 |
内科学 | 45篇 |
神经病学 | 4篇 |
特种医学 | 5篇 |
外科学 | 23篇 |
一般理论 | 2篇 |
预防医学 | 14篇 |
药学 | 13篇 |
肿瘤学 | 204篇 |
出版年
2022年 | 3篇 |
2021年 | 2篇 |
2019年 | 5篇 |
2018年 | 9篇 |
2017年 | 5篇 |
2016年 | 2篇 |
2015年 | 6篇 |
2014年 | 6篇 |
2013年 | 9篇 |
2012年 | 15篇 |
2011年 | 15篇 |
2010年 | 11篇 |
2009年 | 9篇 |
2008年 | 19篇 |
2007年 | 15篇 |
2006年 | 10篇 |
2005年 | 15篇 |
2004年 | 9篇 |
2003年 | 5篇 |
2002年 | 9篇 |
2001年 | 14篇 |
2000年 | 11篇 |
1999年 | 17篇 |
1998年 | 3篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1995年 | 7篇 |
1994年 | 3篇 |
1993年 | 6篇 |
1992年 | 10篇 |
1991年 | 10篇 |
1990年 | 6篇 |
1989年 | 17篇 |
1988年 | 6篇 |
1987年 | 11篇 |
1986年 | 10篇 |
1985年 | 17篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1973年 | 1篇 |
排序方式: 共有354条查询结果,搜索用时 0 毫秒
351.
B Biesma P H Willemse N H Mulder D T Sleijfer J A Gietema R Mull P C Limburg J Bouma E Vellenga E G de Vries 《Blood》1992,80(5):1141-1148
To define the maximum tolerated dose and to study whether recombinant human interleukin-3 (rhIL-3) reduced chemotherapy-induced neutropenia and thrombocytopenia, 20 chemotherapy-naive patients with advanced ovarian cancer eligible for treatment with 6 cycles of carboplatin-cyclophosphamide every 4 weeks (day 1) were entered in a phase I/II open, single-center trial. Cohorts of five patients received during 7 days 1, 5, 10, or 15 micrograms/kg/d rhIL-3 (days 5 through 11) in cycles 1, 3, and 5 by continuous intravenous (IV) infusion or once daily subcutaneous (SC) administration. In control cycles 2, 4, and 6, no rhIL-3 was administered. rhIL-3 significantly increased the recovery of leukocyte, neutrophil, and platelet counts, especially at 5, 10, and 15 micrograms/kg rhIL-3. rhIL-3 also increased basophil, eosinophil, monocyte, and lymphocyte counts at this dose steps. Effects on reticulocytes were limited. No difference in efficacy between SC and IV rhIL-3 treatment was found. Chemotherapy postponement for insufficient bone marrow recovery was necessary in 22 of 45 control cycles versus 2 of 49 rhIL-3 cycles (P less than .001). Platelet transfusions were required in 7 of 45 control cycles versus 3 of 50 rhIL-3 cycles (P less than .5). rhIL-3 up to 10 micrograms/kg/d could be administered without severe side effects. At 15 micrograms/kg/d, rhIL-3 headache was dose-limiting. Other side effects were fever, flu-like symptoms, nausea, skin rash, flushing, facial erythema, and urticaria. Liver toxicity occurred in rhIL-3 and control cycles. rhIL-3 slightly increased tumor necrosis factor alpha, C-reactive protein, and serum amyloid A plasma levels, whereas no effect on IL-6 plasma levels was observed. rhIL-3 administered SC appears to be an interesting hematopoietic growth factor for reduction of chemotherapy-induced myelotoxicity. 相似文献
352.
An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA
Silvia R. Vitale Anieta M. Sieuwerts Nick Beije Jaco Kraan Lindsay Angus Bianca Mostert Esther A. Reijm Ngoc M. Van Ronald van Marion Luc Y. Dirix Paul Hamberg Felix E. de Jongh Agnes Jager John A. Foekens Paolo Vigneri Stefan Sleijfer Maurice P.H.M. Jansen John W.M. Martens 《The Journal of molecular diagnostics : JMD》2019,21(1):123-137
353.
Medical oncology is a relatively young, rapidly growing subspecialty of internal medicine. This discipline will increasingly fulfil a role in the multidisciplinary approach for cancer patients. The fact that the population is rapidly aging, makes it of relevance to train medical oncologists further in the treatment of elderly patients. The growing number of cancer survivors deserves also special attention in order to limit the frequency of long-term side effects. Apart from the classical function as a doctor who treats cancer patients with drugs, the medical oncologist will play an expanding role at the far ends of oncology, namely in prevention and palliative care. Basic sciences create a tremendous amount of new knowledge on cancer detection, behavior and rational drug design. An important task for the medical oncologist will be to translate this expertise to the clinical scenario. The expanding requirement of specific skills of medical oncologists in the next century is likely to cause a further subspecialization within medical oncology. 相似文献
354.
Marrit?A.?Tuinman Joke?Fleer Dirk?Th.?Sleijfer Harald?J.?Hoekstra Josette?E.?H.?M.?Hoekstra-WeebersEmail author 《Supportive care in cancer》2005,13(7):540-548
Goal To compare marital and sexual satisfaction of men who survived testicular cancer (TC) and their spouses to a reference group, and to compare marital and sexual satisfaction of couples who had a relationship at time of diagnosis (couples during TC) to couples who developed a relationship after completion of treatment (couples after TC).Patients and methods Two hundred and nineteen couples during TC and 40 couples after TC completed the Maudsley Marital Questionnaire, a validated instrument to measure marital and sexual satisfaction.Results Survivors and spouses of both couple groups reported similar marital satisfaction as men and women of the reference group. Survivors (t=2.9, p<0.01) and spouses (t=2.9, p<0.01) of couples during TC and survivors of couples after TC (t=1.9, p=0.05) reported less sexual satisfaction than the reference groups. Survivors of couples after TC reported less sexual satisfaction than survivors of couples during TC (F=4.0, p<0.05). Correlations between sexual satisfaction of survivors and spouses in couples during TC (r=0.76, p<0.001) and couples after TC (r=0.77, p<0.001) were high.Conclusion Testicular cancer did not appear to have a negative effect on marital satisfaction in couples during TC, although TC survivors and their spouses reported less sexual satisfaction than men and women of the reference group. Survivors who developed a relationship after completion of treatment seemed to form a vulnerable group: their sexual satisfaction was lower than that of men in the reference group and of TC survivors with a longer relationship. Besides that, they more often reported marital problems than their spouses did. 相似文献